Bromocriptine treatment in adolescent boys with familial tall stature: a pair-matched controlled study.
Recently, bromocriptine has been proposed as a novel agent for the treatment of excessively tall stature in adolescents. To further test its value, we treated nine boys, aged 10.0-15.4 yr, for 1 yr with bromocriptine (7.5 mg/day). A paradoxical plasma GH response to TRH was demonstrated in four of eight boys before and in five boys after 6 months of bromocriptine treatment. At the onset of therapy, the mean adult height prediction was 202.2 +/- 4.3 (+/- SD) cm (Bayley-Pinneau), 202.1 +/- 4.7 cm (TW Mark II), and 198.6 +/- 5.3 cm (Roche-Wainer-Thissen). After 1 yr of therapy, the mean adult height prediction had changed by -4.5 +/- 2.6 cm (Bayley-Pinneau), -3.4 +/- 2.2 cm (TW Mark II), and -2.6 +/- 1.2 cm (Roche-Wainer-Thissen). These reductions were solely due to a decrease in growth velocity and not to an increased skeletal maturation rate. To substantiate these findings, each treated boy was pair-matched with an untreated tall boy so that their chronological and skeletal ages differed by less than 1 yr. After 1 yr of follow-up, height predictions in the treated boys compared with those in the matched control boys gave significantly reduced results with the Bayley-Pinneau and the Roche-Wainer-Thissen, but not with the TW Mark II, method. Because of this discrepancy it is uncertain whether final height in tall boys will really be reduced by treatment with bromocriptine.
D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D001971:Bromocriptine / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D011627:Puberty / Q000187:drug effects; D013973:Thyrotropin-Releasing Hormone
D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone